VENTURA, Maria Teresa
 Distribuzione geografica
Continente #
NA - Nord America 10.554
EU - Europa 4.291
AS - Asia 3.592
SA - Sud America 1.013
Continente sconosciuto - Info sul continente non disponibili 295
AF - Africa 140
OC - Oceania 18
Totale 19.903
Nazione #
US - Stati Uniti d'America 10.289
RU - Federazione Russa 1.595
SG - Singapore 1.500
IT - Italia 871
BR - Brasile 793
CN - Cina 784
HK - Hong Kong 507
SE - Svezia 484
DE - Germania 272
UA - Ucraina 268
FI - Finlandia 214
VN - Vietnam 214
FR - Francia 213
GB - Regno Unito 172
IN - India 131
CA - Canada 98
AR - Argentina 81
BD - Bangladesh 79
ID - Indonesia 68
IQ - Iraq 44
MX - Messico 41
TR - Turchia 37
IE - Irlanda 32
VE - Venezuela 31
ES - Italia 29
PK - Pakistan 29
ZA - Sudafrica 28
CI - Costa d'Avorio 27
CO - Colombia 27
EC - Ecuador 26
MA - Marocco 25
BE - Belgio 23
CR - Costa Rica 23
AT - Austria 22
UZ - Uzbekistan 22
JP - Giappone 21
NL - Olanda 21
MY - Malesia 20
SA - Arabia Saudita 19
PH - Filippine 18
TT - Trinidad e Tobago 17
AU - Australia 15
CL - Cile 15
JM - Giamaica 14
LT - Lituania 14
PL - Polonia 14
PY - Paraguay 14
GT - Guatemala 13
JO - Giordania 13
NI - Nicaragua 13
KZ - Kazakistan 12
EG - Egitto 11
LK - Sri Lanka 11
SV - El Salvador 10
CW - ???statistics.table.value.countryCode.CW??? 9
GP - Guadalupe 9
HN - Honduras 9
KE - Kenya 9
TN - Tunisia 9
UY - Uruguay 9
AE - Emirati Arabi Uniti 8
BO - Bolivia 8
IL - Israele 8
PE - Perù 8
CH - Svizzera 7
DZ - Algeria 7
PR - Porto Rico 7
CZ - Repubblica Ceca 6
ET - Etiopia 6
NP - Nepal 6
PS - Palestinian Territory 6
DO - Repubblica Dominicana 5
KR - Corea 5
PA - Panama 4
RO - Romania 4
AL - Albania 3
BG - Bulgaria 3
IR - Iran 3
KG - Kirghizistan 3
LB - Libano 3
PT - Portogallo 3
SO - Somalia 3
TH - Thailandia 3
AM - Armenia 2
BF - Burkina Faso 2
BY - Bielorussia 2
CG - Congo 2
DK - Danimarca 2
EE - Estonia 2
EU - Europa 2
GE - Georgia 2
HU - Ungheria 2
LA - Repubblica Popolare Democratica del Laos 2
LY - Libia 2
MK - Macedonia 2
NG - Nigeria 2
NO - Norvegia 2
NZ - Nuova Zelanda 2
OM - Oman 2
QA - Qatar 2
Totale 19.591
Città #
Ashburn 940
Fairfield 908
Woodbridge 888
Singapore 744
Chandler 721
San Jose 628
Jacksonville 592
Houston 573
Hong Kong 506
Ann Arbor 383
Nyköping 372
Milan 362
Seattle 362
Wilmington 315
Cambridge 306
Council Bluffs 212
Roxbury 170
Lawrence 169
New York 165
Lauterbourg 151
Nanjing 143
Beijing 142
Los Angeles 107
Des Moines 106
Boardman 105
Dallas 101
Rome 96
Helsinki 83
Santa Clara 68
São Paulo 65
Ho Chi Minh City 62
Inglewood 58
Columbus 53
Bari 52
Dong Ket 52
Jiaxing 47
Princeton 47
Hebei 44
Shenyang 43
Brooklyn 42
San Diego 38
Jakarta 37
London 33
Nanchang 33
Figino 30
Montreal 30
Buffalo 29
Tianjin 29
Hanoi 28
Frankfurt am Main 27
Abidjan 26
Dublin 25
Turin 25
Chicago 24
Ostuni 24
Atlanta 23
Brussels 22
Denver 21
Naples 20
Paris 20
Changsha 19
Nuremberg 19
Rio de Janeiro 19
San Francisco 19
Tashkent 19
Brasília 18
Washington 18
Baghdad 17
Dearborn 17
Guangzhou 17
Taranto 17
Toronto 17
Belo Horizonte 16
Chennai 16
Curitiba 16
Orem 16
Phoenix 16
Shanghai 16
Tokyo 16
Pune 15
Colombo 14
Quito 14
San José 14
Johannesburg 13
Dhaka 12
Guatemala City 12
Managua 12
Mexico City 12
Moscow 12
Porto Alegre 12
Warsaw 12
Wuhan 12
Austin 11
Bologna 11
Campinas 11
Haiphong 11
Istanbul 11
Kingston 11
Kuala Lumpur 11
Redwood City 11
Totale 12.109
Nome #
Adverse reaction to specific immunotherapy for house-dust mite in a patient with Anisakis allergy 837
Latex allergy and sensitization in cities: a survey in a population at risk. Int J Immunopathol Pharmacol. 2006 Oct-Dec;19(4):821-30 713
Allergic and non-allergic rhinitis in swimmers: clinical and cytological aspects 372
THE BASOPHIL ACTIVATION TEST IN THE DIAGNOSIS AND MANAGEMENT OF ADVERSE DRUG REACTIONS IN THE ELDERLY 257
Allergic and psudoallergic reactions induced by glucocorticoids: a review 236
Building bridges for innovation in ageing: Synergies between Action Groups of the EIP on AHA 194
Intramuscular epinephrine as first-line treatment of anaphylaxis: Still concerns about its safety in the elderly? 180
Anisakiasis, an underestimated infection: effect on intestinal permeability of anisakis simplex- sensitized patients 178
Airway inflammation in subjects with gastro-oesophageal reflux and gastro-oesophageal reflux-related asthma 177
A Multicenter Study of IgE Sensitization to Anisakis simplex and Diet Recommendation 174
Immunosenescence in aging: between immune cells depletion and cytokines up-regulation 174
The work productivity and activity impairment allergic specific (WPAI-AS) questionnaire using mobile technology: The mask study 171
Cytokine profile in patients infected with Anisakis simplex in endemic areas: Dietary intervention with polyphenols: A working hypothesis 169
2019 ARIA Care pathways for allergen immunotherapy. 169
Allergic diseases in the elderly: Biological characteristics and main immunological and non-immunological mechanisms 169
Allergic bronchial asthma: eosinophil chemotaxis and antihistaminic drug modulation 159
Management of chronic spontaneous urticaria in the elderly. 159
Adherence to treatment in allergic rhinitis using mobile technology. The MASK Study 159
Guidelines for the use and interpretation of diagnostic methods in adult food allergy 158
Adverse drug reactions as the cause of emergency department admission: focus on the elderly 156
The Psoriasis pathogenesis and the metabolic risk 156
“Importance of hypersensitivity in adverse reactions to drugs in the elderly”. 156
Books: Fundamentals of Immunology 153
Allergic Rhinitis and its Impact on Asthma (ARIA) Phase 4 (2018): Change management in allergic rhinitis and asthma multimorbidity using mobile technology 153
Allergic contact dermatitis due to epirubicin 152
Antiinflammatory effects of H1-antihistamines: clinical and immunological relevance 147
Next-generation ARIA care pathways for rhinitis and asthma: a model for multimorbid chronic diseases. 147
Clinical data and inflammation parameters in patients with cypress allergy treated with sublingual swallow therapy and subcutaneous immunotherapy 143
Drug hypersensitivity cutaneous diseases in the elderly 143
Non-specific immunity in aging: deficiency of monocyte and polymorphonuclear cell-mediated functions 142
ARIA 2016: Care pathways implementing emerging technologies for predictive medicine in rhinitis and asthma across the life cycle. 142
Sensitization, asthma and allergic disease in young soccer players 141
A survey of clinical features of allergic rhinitis in adults 140
Daily allergic multimorbidity in rhinitis using mobile technology: A novel concept of the MASK study 139
Mobile technology offers novel insights into the control and treatment of allergic rhinitis: The MASK study. 134
Adherence issues related to sublingual immunotherapy as perceived by allergists 133
Anaphylaxis induced by intramuscular betamethasone disodium phosphate: reflections on a clinical case 132
Validation of the MASK-rhinitis visual analogue scale on smartphone screens to assess allergic rhinitis control. 132
Management of allergic disease in the elderly: key considerations,recommendations and emerging therapies 132
Guidance to 2018 good practice: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma 132
Shrimp allergy: analysis of commercially available extracts for in-vivo diagnosis. 131
Clinical and cytologic characteristics of allergic rhinitis in elderly patients 130
Choosing wisely: practical considerations on treatment efficacy and safety of asthma in the elderly. 130
Positioning the principles of precision medicine in care pathways for allergic rhinitis and chronic rhinosinusitis - A EUFOREA-ARIA-EPOS-AIRWAYS ICP statement. 130
Clusterin serum level: how does it affect psoriatic patients? 130
Human melanoma metastasis culture supernatant contains chemotactic factors for phagocytes 129
Use of complementary medicine among patients with allergic rhinitis: an Italian nationwide survey. 129
Contact dermatitis in students practicing sports: incidence of rubber sensitisation 128
Urban air pollution and climate change: "The Decalogue: Allergy Safe Tree" for allergic and respiratory diseases care 128
A RETROSPECTIVE SAFETY-MONITORING STUDY OF ADVERSE REACTION OCCURRING DURING IMMUNOTHERAPY: AN EPIDEMIOLOGICAL EVALUATION 127
Anisakis simplex hypersensitivity is associated with chronic urticaria in endemic areas. 123
Correlation between work impairment, scores of rhinitis severity and asthma using the MASK-air® App 123
Modulating effects of monocytes and autologous serum on natural killer capacity in multiple myeloma patients 122
An approach to urticaria in the elderly patients 120
Tolerance to etoricoxib in 37 patients with urticaria and angioedema induced by nonsteroidal anti-inflammatory drugs 118
Geolocation with respect to personal privacy for the Allergy Diary app - a MASK study 118
How to fit allergen immunotherapy in the elderly 118
Advances in diagnosing drug hypersensitivity reactions 116
Allergic contact dermatitis from timolol complicating choroidal melanoma-related glaucoma 116
Heterogeneous catalysts for the selective aerobic oxidation of 5-hydroxymethylfurfural to added value products in water 116
Aligning the Good Practice MASK With the Objectives of the European Innovation Partnership on Active and Healthy Ageing 116
Validity and reproducibility of morphologic analysis of nasal secretions obtained using ultrasonic nebulization of hypertonic solution. 115
Lipoprotein-induced inhibition of plaque-forming cell generation and natural killer cell frequency in aged donors 114
Retrospective study on fluticasone propionate aqueous nasal spray efficacy in patients with allergic rhinitis: evaluation of clinical and laboratory parameters 113
Eosinophils in allergic diseases: immunopharmacological regulation 113
Diet and myocardial infarction: a nested case-control study in a cohort of elderly subjects in a Mediterranean area of southern Italy 113
ARIA pharmacy 2018 "Allergic rhinitis care pathways for community pharmacy". 112
[Cell-mediated immunity in drug addicts: interaction of opiates and naloxone on natural cytotoxic activity and immune-mediated reactions of phagocytes] 111
MASK 2017: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma multimorbidity using real-world-evidence. 111
Intestinal permeability in patients with adverse reactions to food 110
Latex allergy and sensitization in cities: a survey in a population at risk 108
. An Update on the Diagnosis of Allergic and Non-Allergic Drug Hypersensitivity 108
Anisakis Simplex Infestation and immune-mediated responses. 108
Hypersensitivity reactions to complementary and alternative medicine products 108
A critical approach to an allergic paradox: allergic and allergic-like reactions to glucocorticoids. Delayed hypersensitivity mechanisms 107
Relationship between human lipoproteins and interferon-alfa on natural killer cytotoxicity at the single cell level. 107
The Characteristics of Severe Chronic Upper-Airway Disease (SCUAD) in Patients with Allergic Rhinitis: A Real-Life Multicenter Cross-Sectional Italian Study. 107
Effects of in vitro nutrient supplementation on polymorphonuclear cell respiratory burst in primary IgA nephropathy 106
Evaluation of D-dimer levels in obliterating arteriopathies 105
Vitamin D levels and allergic diseases. An italian cross-sectional multicenter survey. 105
Next-generation Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines for allergic rhinitis based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) and real-world evidence. 105
Incidence of allergic diseases in an elderly population 104
Transfer of innovation on allergic rhinitis and asthma multimorbidity in the elderly (MACVIA-ARIA) - EIP on AHA Twinning Reference Site (GARD research demonstration project) 104
Next-generation care pathways for allergic rhinitis and asthma multimorbidity: a model for multimorbid non-communicable diseases-Meeting Report (Part 1). 104
Allergy immunotherapy across the life cycle to promote active and healthy ageing: from research to policies: An AIRWAYS Integrated Care Pathways (ICPs) programme item (Action Plan B3 of the European Innovation Partnership on active and healthy ageing) and the Global Alliance against Chronic Respiratory Diseases (GARD), a World Health Organization GARD research demonstration project. 104
Latex and amoxicillin-provoked occupational asthma 103
Sensitization to Horse Allergens in Italy: A Multicentre Study in Urban Atopic Subjects without Occupational Exposure 103
Immunocompetens and nutrient deficiency in the elderly. 102
Cutaneous adverse drug reactions to Fluticasone Propionate and Deflazacort in an asthmatic patient 101
Is black henna responsible for asthma and cross reactivity with latex? 101
CHRODIS criteria applied to the MASK (MACVIA-ARIA Sentinel NetworK) Good Practice in allergic rhinitis: A SUNFRAIL report 101
IgE, IgG1 and IgG4 response to specific allergens in sensitized subjects showing different clinical reactivity to Anisakis simplex 100
In vitro modulating effect of zinc chloride and human lipoproteins on phagocytic activity in the elderly. 99
Hypersensitivity reactions to ophthalmic products 99
Anaphylaxis to hydrocortisone hemisuccinate with cross-sensitivity to related compounds in a pediatric patient 97
Allergy, asthma and markers of infections among Albanian migrants to Southern Italy 97
Alternative glucocorticoids for use in cases of adverse reaction to systemic glucocorticoids: a study on 10 patients 96
Relationship between immune system and gram-negative bacteria. II. Natural killer cytotoxicity of Salmonella minnesota Rb 345-unbound human peripheral blood lymphocytes 96
Cross-reactivity in cell-mediated and IgE-mediated hypersensitivity to glucocorticoids 96
Histamine modulation of polymorph and eosinophil chemotactic responsiveness in healthy donors. 95
Totale 14.496
Categoria #
all - tutte 75.636
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 75.636


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022832 0 0 0 72 46 71 26 61 75 62 157 262
2022/20231.844 268 152 138 204 233 255 13 165 350 13 33 20
2023/2024576 49 129 25 22 33 133 9 22 20 23 24 87
2024/20252.397 130 33 258 59 64 203 147 172 125 102 367 737
2025/20266.252 656 168 350 570 481 272 654 145 1.734 444 145 633
2026/20271.916 304 457 447 708 0 0 0 0 0 0 0 0
Totale 19.903